Aberrant basal ganglia metabolism in fragile X syndrome: a magnetic resonance spectroscopy study

Table 1 Cognitive measures and medications

Measure	Group	N	Mean	Minimum	Maximum	SD
Age	FXS	18	20.54	15.39	25.85	3.57
Age	Comparison	18	19.80	16.59	25.85	2.61
Verbal IQ	FXS	18	80.22	46	119	21.08
Verbal IQ	Comparison	18	72.56	46	100	18.77
Performance IQ	FXS	18	72.78	48	118	18.46
Performance IQ	Comparison	18	76.89	55	121	20.36
Full Scale IQ	FXS	18	74.56	44	119	20.61
Full Scale IQ	Comparison	18	72.72	48	111	19.68
Contingency Naming Test (CNT)	FXS	16	17.73	6.61	47.65	10.32
Contingency Naming Test (CNT)	Comparison	16	17.02	4.29	36.00	9.93
Aberrant Behavior Checklist	FXS	15	19.33	0	90	24.85
Aberrant Behavior Checklist	Comparison	17	19.65	0	74	19.68
Achenbach attention	FXS	17	59.65	50	83	9.36
Achenbach attention	Comparison	17	62.35	50	75	6.70
Medications		N	Percent (%)
SSRI	FXS	4	22.22
SSRI	Comparison	3	16.67
Stimulants	FXS	2	11.11
Stimulants	Comparison	7	38.88
Other	FXS	4	22.22
Other	Comparison	0	0
Medication-free	FXS	10	27.78
Medication-free	Comparison	10	27.78

Standard scores are reported for Verbal, Performance and Full Scale IQ; higher scores indicate better performance. The CNT score is the number of items correct (out of 27) divided by the time to completion; higher scores indicate better performance. Raw scores are reported for the Aberrant Behavior Checklist; higher scores indicate greater prevalence of aberrant behavior. Achenbach attention refers to the Adult or Child Behavior Checklist attention subscale, T scores are reported for this test (range = 1 to 100, mean = 50); higher scores indicate greater attention problems. CNT Contingency Naming Test, FXS fragile X syndrome, IQ intelligence quotient, Other, atypical antipsychotics, anticonvulsants and other drugs affecting neurological functioning; SSRI selective serotonin reuptake inhibitor.

ISSN: 1866-1955